Back to Search
Start Over
Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis.
- Source :
-
Internal medicine (Tokyo, Japan) [Intern Med] 2010; Vol. 49 (20), pp. 2211-8. Date of Electronic Publication: 2010 Oct 15. - Publication Year :
- 2010
-
Abstract
- Objective: Mizoribine (MZR) is an immunosuppressant that inhibits nucleic acid metabolism and is a relatively safe disease-modifying anti-rheumatic drug (DMARD). We evaluated the efficacy and safety of one single dose per day for patients with rheumatoid arthritis (RA).<br />Patients and Methods: In this study 32 patients with RA received MZR therapy. We evaluated the average dose of MZR and prednisolone, response to treatment and peak plasma level of MZR.<br />Results: The average dose of MZR was 146.1±31.2 (range: 50-200) mg/day. The average dose of prednisolone was 4.63±3.59 (range: 0-14) mg/day. The average plasma level of MZR, measured after 3 hours, was 2.20±0.49 µg/mL in the responder group and 1.59±0.82 µg/mL in the non-responder group (p=0.020). The treatment with MZR for 24 weeks was completed by 71.9% of patients and the proportion of patients who achieved a good and moderate response rate according to the European League Against Rheumatism (EULAR) criteria was 56.3% at 24 weeks. The plasma level of MZR which was greater than or equal to 2.12 µg/mL was significantly correlated with the clinical response (p<0.01). Only one of thirty-two cases discontinued the treatment, because of skin eruption.<br />Conclusion: This study included patients that could not be treated with other DMARDs and/or biologic agents because of age, interstitial pneumonia and other complications. We show that MZR may be a useful and relatively safe therapy for patients in this group.
- Subjects :
- Adult
Aged
Aged, 80 and over
Antirheumatic Agents administration & dosage
Antirheumatic Agents adverse effects
Antirheumatic Agents blood
C-Reactive Protein analysis
Drug Administration Schedule
Drug Therapy, Combination
Female
Humans
Immunosuppressive Agents administration & dosage
Immunosuppressive Agents adverse effects
Immunosuppressive Agents blood
Male
Middle Aged
Pilot Projects
Prednisolone administration & dosage
Prednisolone therapeutic use
Ribonucleosides administration & dosage
Ribonucleosides adverse effects
Ribonucleosides blood
Treatment Outcome
Antirheumatic Agents therapeutic use
Arthritis, Rheumatoid drug therapy
Immunosuppressive Agents therapeutic use
Ribonucleosides therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1349-7235
- Volume :
- 49
- Issue :
- 20
- Database :
- MEDLINE
- Journal :
- Internal medicine (Tokyo, Japan)
- Publication Type :
- Academic Journal
- Accession number :
- 20962439
- Full Text :
- https://doi.org/10.2169/internalmedicine.49.3810